TY - JOUR
T1 - Indazole estrogens
T2 - Highly selective ligands for the estrogen receptor β
AU - De Angelis, Meri
AU - Stossi, Fabio
AU - Carlson, Kathryn A.
AU - Katzenellenbogen, Benita S.
AU - Katzenellenbogen, John A.
PY - 2005/2/24
Y1 - 2005/2/24
N2 - The estrogen receptors, ERα and ERβ, are important pharmaceutical targets. To develop ERβ-selective ligands, we synthesized a series of nonsteroidal compounds having a phenyl-2H-indazole core with different groups at C-3. Several of these show high affinity and good ERβ selectivity, especially those with polar and/or polarizable substituents at this site (halogen, CF3, nitrile); the best compounds have affinities for ERβ comparable to estradiol, with ERβ affinity selectivity >100. This potency and ERβ selectivity is also seen in cell-based transcriptional assays, where several compounds showed ERβ efficacies equivalent to that of estradiol with ERβ potency selectivities of 100. These compounds might prove useful as selective pharmacological probes to study the biological actions of estrogens mediated through ERβ, and they might lead to the development of useful pharmaceuticals. These findings also contribute to an evolving pharmacophore that characterizes certain nonsteroidal ligands having high ERβ subtype affinity and potency selectivity.
AB - The estrogen receptors, ERα and ERβ, are important pharmaceutical targets. To develop ERβ-selective ligands, we synthesized a series of nonsteroidal compounds having a phenyl-2H-indazole core with different groups at C-3. Several of these show high affinity and good ERβ selectivity, especially those with polar and/or polarizable substituents at this site (halogen, CF3, nitrile); the best compounds have affinities for ERβ comparable to estradiol, with ERβ affinity selectivity >100. This potency and ERβ selectivity is also seen in cell-based transcriptional assays, where several compounds showed ERβ efficacies equivalent to that of estradiol with ERβ potency selectivities of 100. These compounds might prove useful as selective pharmacological probes to study the biological actions of estrogens mediated through ERβ, and they might lead to the development of useful pharmaceuticals. These findings also contribute to an evolving pharmacophore that characterizes certain nonsteroidal ligands having high ERβ subtype affinity and potency selectivity.
UR - http://www.scopus.com/inward/record.url?scp=13944255737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=13944255737&partnerID=8YFLogxK
U2 - 10.1021/jm049223g
DO - 10.1021/jm049223g
M3 - Article
C2 - 15715479
AN - SCOPUS:13944255737
SN - 0022-2623
VL - 48
SP - 1132
EP - 1144
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 4
ER -